## Supplement to: Natriuretic effect of 2 weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: Results of the DAPASALT trial

Scholtes R.A. et. al.

## Content:

Supplementary Table 1: Changes in primary and secondary outcomes in the intention to treat population (N=15)

Supplementary Table 2: 24-hour sodium, glucose, urine excretion at each collection day

Supplementary Table 3: Adverse events

Supplementary Figure 1: Study design

Supplementary Table 1: Changes in primary and secondary outcomes in the intention to treat population (N=15)

		Change fro	Change from		
			End of Treatment		
	Baseline	Start of Treatment	End of Treatment	Follow-up	
		(Day 2-4)	(Day 12-14)	(Day 15-17)	
	Mean (SD)	Mean change (95% CI)	Mean change (95% CI)	Mean change (95% CI)	
24-hour sodium excretion	147.37	-5.21	3.69	-16.72	
(mmol/24 hour)	(32.17)	(–19.54, 9.12)	(–24.82, 32.20)	(–34.11, 0.66)	
24-hour glucose excretion	1.80	344.85	311.30	-203.07	
(mmol/24 hour)	(2.16)	(272.79, 416.91)	(224.53, 398.06)	(–235.98, –170.16)	
24-hour volume excretion	2238.08	57.23	108.68	-214.33	
(mL/24 hour)	(594.82)	(-206.00, 320.47)	(–170.27, 387.63)	(–437.15, 8.49)	
24-hour systolic blood pressure	127.00	-5.27	-7.10	0.73	
(mmHg)	(10.28)	(-8.55, -1.99)	(–10.04, –4.16)	(–1.99, 3.45)	
Body weight (kg)	97.75	-0.73	-1.68	0.45	
	(15.77)	(-1.12, -0.35)	(-2.37, -1.00)	(0.02, 0.89)	
Plasma volume (L)	2 69 (0 79)	0.03	-0.43	0.48	
	3.68 (0.78)	(-0.73, 0.79)	(–1.08, 0.21)	(0.10, 0.85)	
Extracellular volume (L)	20.93	-0.67	-0.03	0.17	
	(4.32)	(–1.19, –0.15)	(-0.46, 0.40)	(-0.14, 0.48)	
Intracellular volume (L)	26.41	-0.27	0.14	-0.33	
	(5.54)	(-0.90, 0.35)	(-0.52, 0.79)	(-0.66, -0.00)	

Supplementary Table 2: 24-hour sodium, glucose, urine excretion at each collection day

Period		Run-in			Dapagliflozin 10 mg/day treatment					Wash-out			
Day	-3	-2	-1	1	2	3	4	12	13	14	15	16	17
Sodium	161	153	129	156	156	136	136	153	166	135	137	138	143
(mmol/24 hour)	(42)	(33)	(36)	(45)	(37)	(42)	(31)	(54)	(79)	(79)	(50)	(38)	(41)
Glucose	2	2	3	258	369	338	351	325	321	327	202	94	54
(mmol/24 hour)	(2)	(2)	(4)	(57)	(134)	(143)	(141)	(148)	(144)	(172)	(135)	(107)	(79)
Volume	2437	2269	1988	2148	2411	2401	2201	2474	2487	2136	2341	2137	2125
(mL/24-hour)	(537)	(666)	(699)	(726)	(710)	(874)	(619)	(857)	(868)	(690)	(568)	(696)	(631)

Data are provided as mean (SD)

Supplementary Table 3: Adverse events

Variable	Dapagliflozin (N=17)*			
Any Adverse Events	6 (35.3)			
Any Serious Adverse Events	0 (0.0)			
Any Adverse Event leading to drug discontinuation	0 (0.0)			
Adverse Events related to dapagliflozin#	4 (23.5)			
Adverse Events of interest <sup>†</sup>				
Hypoglycemia	0 (0.0)			
Genital infection	1 (5.9)			


\*Safety population (N) comprised 17 patients who took at least 1 dapagliflozin tablet.


<sup>#</sup>In the opinion of the Investigator.

Data are expressed as number of patients in each category, n (%).Patients with multiple events

in the same category are counted only once in that category.

<sup>†</sup>Based on MedDRA (Medical Dictionary for Regulatory Activities) preferred term.





Dietary advice, food questionnaires and sodium-controlled diet (Na<sup>+</sup> 150 mmol/24-hour)

- 🗱 = Blood and urine samples collected, bioimpedance spectroscopy measurements and plasma volume measurements were performed at Day 1, Day 4, Day 14 and Day 18.
- = 24-hour urine assessment was performed at BL (Days -3 to -1), ST (Days 2 to 4), ET (Days 12 to 14) and FU (Days 15 to 17).
- 24-hour urine collection (not included in assessment).
  - BL, baseline; ST, start of treatment; ET, end of treatment; FU, follow-up